A three-year study of tirzepatide (Mounjaro/Zepbound) found that when adults who had prediabetes and obesity or overweight used it weekly, it lowered their risk of progression to diabetes by 94%
— A three-year study of tirzepatide – a medication approved in the US as Zepbound for diabetes and Mounjaro for weight loss – found that when adults who had prediabetes and obesity or overweight used it weekly, it lowered their risk of progression to diabetes by 94% compared with a placebo, according to drugmaker Eli Lilly & Company.The company said Tuesday that people who got a 15-milligram dose of the medicine also had an average decrease in body weight of nearly 23%, compared with 2.
It affects about 1 in 3 adults in the US – 84 million people – and about 70% will go on to be diagnosed with diabetes. Lifestyle changes – especially weight loss – have generally been considered the most important management tool.Tirzepatide works by mimicking hormones that stimulate the release of insulin, increase feelings of fullness and reduce appetite. It targets two hormone receptors, GIP and GLP-1.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Lilly's weight-loss drug cuts diabetes risk by 94% in three-year trial, company saysIn one of the first studies of its kind, people lost more weight taking Mounjaro and Zepbound than Ozempic and Wegovy. The drugs have different active ingredients, and doctors say they are both effective for weight loss. Which one is prescribed depends on the needs of the patient. NBC News' Stephanie Gosk reports.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Jacksonville Jaguars' Trevor Lawrence Ranks No. 94 on NFL Top 100 ListThe fourth-year quarterback is on the list for the second time in his career.
Read more »